361 Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

361 Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,945	Closed	-$1.18M	–	411
2019 Q4	$1.18M	Buy	10,945 +3,972	+57%	+$425K	0.33%	181
2019 Q3	$683K	Sell	6,973 -3,752	-35%	-$423K	0.13%	244
2019 Q2	$1.41M	Sell	10,725 -71	-0.7%	-$9.15K	0.25%	188
2019 Q1	$1.46M	Buy	+10,796	New	+$1.34M	0.25%	178

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

361 Capital's ALXN Position: Q1 2020 in Review

361 Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 10,945 shares — an estimated $1.18M sold.

361 Capital first reported a position in ALXN in Q1 2019 and held it in 4 quarters. The position peaked at $1.46M in Q1 2019. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

361 Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
361 Capital sold 10,945 Alexion Pharmaceuticals shares in Q1 2020, an estimated $1.18M.
361 Capital first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 4 quarters.
361 Capital's Alexion Pharmaceuticals position peaked at $1.46M in Q1 2019.
654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.